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Adaptation of CAPD patients to the continuous peritoneal
energy uptake
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Continuous ambulatory peritoneal dialysis (CAPD) treatment
is the first continuously working detoxification procedure ap-
plied to uremic patients. However, the uninterrupted exposure
of artificial fluids to the organism is accompanied by some side
effects among which the continuous absorption of D-glucose
from the dialysate is unequivocal: Figures presented in avail-
able literature report from approximately 50 to 200 g per day [1—
3]. Excess energy uptake is currently regarded to be one major
risk factor for the development of atherosclerosis and diabetes
mellitus. The continuing absorption of large amounts of D-
glucose from the dialysate therefore would add to the already
enlarged cardiovascular risk of patients on maintenance dialy-
sis. However, in recent years clinical observations of CAPD
patients have indicated that no seriously dangerous conse-
quences in metabolism are initiated. The patients obviously
develop a mechanism enabling them to compensate for the
continuous peritoneal energy uptake.
The aim of this investigation is to quantify mechanisms by
which an adaptation to this mandatory energy uptake occurs.
This was accomplished by determining the distribution of
energy uptake fractions in nutrition and dialysate of CAPD
patients with a free choice of food. In addition, the responses of
insulin and growth hormone to an oral D-glucose tolerance test
were evaluated. Furthermore, the course of lipid concentration
in serum was studied over a period of approximately 2 years.
The results show that a change in the nutritional habits is
responsible for the adaptation to the peritoneal D-glucose
uptake. Additionally, hormone abnormalities, specific for ure-
mia, are improved in CAPD. However, a significant rise in
cholesterol serum concentration must be noticed.
Methods
Patients. Fifteen patients (7 females, 8 males) with endstage
renal failure were treated with CAPD. The average age was 55.6
+ 11.5 (SD) with the range, 33 to 77 years.
The patients investigated suffered from the following kidney
diseases: nephrosclerosis (1), chronic glomerulonephritis (5),
interstitial kidney disease (4), amyloidosis (1), and diabetic
nephropathy (4).
At the time of the investigation the patients were in clinically
stable condition. Four patients were insulin-dependent diabet-
ics. They were excluded from the oral D-glucose tolerance test
(OGTT) tests.
Dialysis. All patients were treated with intermittent peritone-
al dialysis (IPD) before CAPD was started. The IPD procedure
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followed current practice [4]. The dialysate used was Peritofun-
din (B. Braun Melsungen GmbH, Melsungen, Federal Republic
of Germany). CAPD was performed as described previously
[3]. The solution used was Dianeal® (Baxter Travenol, Deer:
field, Illinois) composed of D-glucose H20 1.5 glliter (4.25 g/
liter, Na 132, Ca 3.0, Mg 1.5, Cl 101.5, and lactate 35
(mmoleslliter).
The patients were instructed to use four exchanges, each of 2
liters per day, one of them with a high D-glucose concentration.
Occasionally, the patients deliberately used two bags of the
high osmolar solution to correct excess fluid intake. One patient
exchanged only 4.6 liters per day.
Study design. OGTT with insulin and human growth hormone
response with a 100-g D-glucose challenge was performed [5].
No special diet was given prior to the test and the patients
fasted for 12 hr and rested for 0.5 hr before the beginning of the
OGTT. The tests were performed during IPD with a low
osmotic solution (that is, 1.5% dextrose) between two IPD
sessions and during CAPD 3 months after the transfer from
IPD, again with a low osmotic dialysate in the peritoneal cavity.
At each venipuncture time (0, 30, 60, 120, and 180 mm) a blood
specimen for insulin and growth hormone analysis was drawn.
Lipid serum concentration course. The patients were called
to the outpatient clinic for routine examination in fasting
conditions approximately every 6 weeks. At this time the lipid
concentration in the serum was determined.
Dietary survey. A 12- to 14-day survey of the dietary habits of
CAPD patients was performed after an adaptation phase of at
least 3 months. Table 1 shows the clinical parameters of the
patients who participated. The patients were urged not to
change their eating habits during the study period. The food
consumed was weighed by means of a laboratory balance with
automatic tare deduction and was precisely recorded. Every
day this procedure was checked by visits at the patient's home.
During the study, dialysate and urine was collected for chemical
analysis at 24-hr intervals comprising total protein and D-
glucose.
Chemical analysis. The following chemical methods were
used (1) D-glucose in blood and dialysate, Glucose oxidase
method, Boehringer, Mannheirn, Germany; (2) lactate in dialy-
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Table 2. Peritoneal energy transfer in CAPD patients
1)-glucose Total protein Lactate
Mean (5EM)
g/24 hr 117.0 (13.5) 8.75 (0.27) 20.54 (0.31)
mole/24 hr 0.65 (0.075) 0.228 (t).0t134)
kJ/24 hr 802 (208.6) 146.1 (4.5) 301.5 (4.6)
N(n) 7 (84) 6 (90) 4 (74)
Abbreviations: N, number of patients; n, number of determinations.
sate, ACA Dupont; (3) triglycerides in serum, triglyceride rapid
test, Roche Laboratories Nutley, New Jersey; (4) cholesterol in
serum, CHOD-PAP Method Boehringer, Mannheim, Germany;
(5) total protein in dialysate; modified Biuret method [6]; (6)
insulin activity in serum, RIA-gnost Insulin Behring Werke,
Morburg, West Germany; (7) growth hormone activity in se-
rum, RIA-gnost hGH Behring Werke.
Calculations and statistics. The energy contents of the food
and the energy-containing substrates transferred across the
peritoneum were calculated using the following numerical fac-
tors: 1 g D-glucose = 16.6 kJ; 1 g carbohydrates from food =
17.1 kJ; 1 g fat = 37.5 kJ; I g protein = 17.1 kJ.
The food components, carbohydrates, fat, and protein were
calculated from the diet records using the nutritional value
tables from Documenta Geigy 1971 71. The energy provided by
lactate was estimated to be 14.7 kJ/g according to the energy
yield of the Embden-Meyerhof degradation [8]. Standard statis-
tics (mean, 5EM, and paired t test) were calculated according to
Documenta Geigy 1971. All calculations were performed on a
Hewlett-Packard microcomputer, Model 85, using Hewlett-
Packard software.
Results
Energy distribution. 'Fable 2 shows the average substrate
transfer across the peritoneum in CAPD patients. The major
share is contributed by D-glucose in the dialysate. The figures
demonstrate that 78.5% of the peritoneal load is absorbed. The
absorption of lactate is of minor importance, although even
81.5% of the load is retained. Because the energy equivalent of
the protein loss is a substraction from the energy absorbed,
lactate and proteins may he considered to annihilate each other
as a sufficient approximation. Therefore, the error introduced is
2.0% of the total energy uptake (Table 3). The further calcula-
tions are only based on the D-glucose contribution to the total
energy balance.
Table 3 depicts the energy uptake from the food as deter-
mined by the dietary survey and from the dialysate as deter-
mined by chemical measurements. The results can be demon-
strated in the following average figures: The fat uptake is
approximately 70 g, the protein uptake about 50 g, and the
carbohydrate uptake about 240 g per day. The protein uptake is
remarkably low, This is especially true if the peritoneal protein
loss of about 8.5 g per day is considered, 'l'hus, the net protein
uptake is only 40 g per day equivalent to 0.69 g!kg day. in terms
of energy, fat is the major source if only the oral route is
regarded (2700 ki per day). The inclusion of the peritoneal D-
glucose uptake, however, restores this altered uptake pattern to
the physiological state of nutrition providing 120 g of carbohy-
drates per day.
This becomes impressively evident if the percentage figures
are compared with the normal energy disti-ibution figures as it is
done in Figure 1. The left panel shows the oral energy ratios
alone whereas in the right panel both the oral and the peritoneal
routes are included in the energy ratios, For comparison the
normal ratio hands are depicted. The total energy uptake in the
group investigated amounts to 126.7 kJ per kg body weight and
day. It should be stressed that the condition under which the
investigation was carried out was a free, almost uninfluenced,
choice of food.
Oral glucose tolerance tests with hormone response. The
results of the diet study may be taken as indicative that the
carbohydrate metabolism is not disturbed in the CAPD situa-
tion since carbohydrate overloading is avoided, indeed, the
OGTT's support this presumption. Figure 2 depicts those tests
in IPD and those repeated in the same patients in CAPD
afterwards but not before 3 months on CAPD had elapsed. The
blood sugar curves demonstrate a mild diabetic reaction which
is almost identical in all three modalities. The 90- and 120-mm
value is unequivocally pathologic, whereas all other blood sugar
levels are in the normal range. The insulin response to the blood
sugar course shows the typical pattern of a maturity onset
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Table 1. Clinical data of the dietary survey group
2
60 60 58 78 69 50
Sex F F M M M PcI M
Diagnosis Chronic
glomerulonephritis
Nephro- Interstitial Diabetic Interstitial
sclerosis nephropathy nephropathy nephropathy
Interstitial
nephropathy
Diabetic
nephropathy
Month on therapy 10 8 7 6 7 10 3
Serum parameters
Hemoglobin,
gIdi 8.5 12.4 11.3 9.0 7.5 12.1 12.4
Creatinine,
mgldt 9.4 7.1 10.0 11.4 ltt.4 8.0 9.2
Urea nitrogen,
mgld/ 57.0 22.9 45.2 39.2 45.3 35.1 28.0
Potassium,
minoles/titer 3.3 3.8 3.9 3.9 5.3 3.4 3.1
7
-
 
-
.
 
01
 
00
1 
—
 
P4
 
00
10
01
 
00
00
 
00
10
01
0 
I 
I• 
I 
I 
:7
7 
0 0 '9 0 01 0 P4 0 0 0 0/
 
0 01 0 P4 C 0 
I 
I 
_
_
_
_
 
\ \ I \ I 
60
1 !II IL• FtII
C)
, !
!flflfinnlM}_i'I .II
•;'
o
40
30
••IHI
TÔT
.1 -
SI.LIII !ia'!'C
a,
———
- I
.
I
Patientno. 1 2 3 4 5 6 7 1234567
Continuous peritoneal energy uptake in CAPD
L.
0
E
0)
0
C)
I
31
without dialysate glucose with dialysate glucose
Fig. 1. Distribution of energy intake in seven CAPD patients. The
fractions of carbohydrates, fat, and proteins are expressed as the
percentage of total energy supply. Left panel demonstrates a situation
without consideration of dialysate absorption of D-glucose. Right panel
includes the absorption of D-glucose. Normal ranges are depicted as
bands. The values are presented as mean SD calculated from the daily
food protocols. Symbols: carbohydrates •; fat 0; protein 0.
diabetes with hyperinsulinism. The hormone reaction is identi-
cally enlarged and delayed in all three peritoneal dialysis states.
Growth hormone, however, shows a different reaction to the
oral D-glucose challenge. In IPD and IPD interval the hormone
levels rise significantly until the 60th mm and decline thereafter
but do not reach the fasting level at the end of the test at the
180th mm. In CAPD this rise is reversed to a significant fall
when compared to the IPD levels. At the 180th mm growth
hormone rises again which is statistically insignificant, howev-
er. Table 4 depicts the fasting levels of blood sugar, insulin, and
growth hormone, obtained in the OGTT's. Statistically signifi-
cant differences cannot be observed in any of the three parame-
ters at each of the various modalities. One may note, however,
that in CAPD insulin and growth hormone fasting levels are
lower than in IPD during dialysis.
In neither of the peritoneal dialysis states an unequivocal
hyperinsulinism in the fasting condition appears which can be
seen by comparison with the normal values. Growth hormone
levels, however, are elevated in CAPD and IPD conditions by a
factor of 1.5 to 2.
Course of serum cholesterol and triglycerides. Figures 3 and
4 illustrate the course of serum triglycerides and serum choles-
terol during the IPD prephase and during the CAPD period
investigated. The linear regression line is depicted for orienta-
tion. No change occurred in triglycerides. The correlation
coefficient is insignificant (r =
—0.06). For cholesterol, howev-
er, an increase appears over the time after the onset of CAPD.
The correlation of cholesterol levels with duration of CAPD is
low (r = 0.27), but significant (P < 0.05).
A paired t test of the mean concentration values before
CAPD and after 1 year of duration did not show a statistical
difference concerning the triglycerides: before CAPD, 398 71
(sEM) mg/dl; after 1 year, 425 80.7 mg/dl (sEM) (P> 0.5). In
the case of cholesterol the difference found is significant: before
CAPD, 254 13 (sEM) mg/dl; after 1 year, 354 394 (sEM) mgi
dl, (P < 0.01).
I
Time, mm
IPD during dialysis IPD interdialytic CAPD
Fig. 2. Oral D-glucose tolerance test (OGTT) performed during IPD and
the interdialytic interval associated. The test was repeated in the same
patients 3 months after the transfer to CAPD. Shaded area in the upper
section is the pathological area. Middle and lower sections refer to
insulin and growth hormone responses. Values are mean and SEM
determined in 11 patients.
Discussion
The purpose of this study was to contribute data to the
current discussion about side effects of CAPD. Therefore, no
selection of patients was made, and accordingly, insulin-depen-
dent diabetics were included. This may be acceptable if more
general findings rather than detailed information on metabolism
under CAPD conditions are desired. Within these limits one
may regard the three major results of this study to be of general
validity for CAPD patients: (1) adaptation of oral carbohydrate
intake to the obligatory peritoneal D-glucose absorption; (2)
reverse of growth hormone secretion after oral D-glucose
challenge to the physiological reaction; (3) elevation of serum
cholesterol levels.
The spontaneous nutrition of CAPD patients is distinguished
from the usual dietary behavior of central Europeans [9] in the
area of proteins and carbohydrates. The protein consumption is
small but lies within the limits of a low protein diet prescribed
for severe renal insufficiency [101. Signs of protein malnutrition
had not been detected in these patients as reported previously
[111. The CAPD patients obviously suppress the oral carbohy-
drate fraction in their nutrition to compensate for the peritoneal
D-glucose absorption. In CAPD the physiological distribution
of nutritional energy sources is maintained. The behavioristic
mechanism by which this is accomplished remains unclear.
Some afferent signals of metabolism must reach the cortical
arrays which are responsible for degustational sensations. The
result, however is unequivocal; energy overloading is avoided
since the organism recognizes the peritoneal energy uptake. It
is speculative, although appealing to hypothesize, that satura-
tion of an intracellular glucoreceptor is responsible for those
signals. To support this speculation one may recall that the
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Table 3. Fractions of 24-hr energy uptake in seven CAPD patients'
117.0 1805.2 122.2 2078.1 71.3 2710.4 48.9 831.3
(13.5) (208.6) (7.3) (123.6) (4.7) (178.4) (2.7) (46.3)
Data represent the mean of 12 to 14 days; SaM is in parentheses,
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Fig. 3. Course of serum triglyceride concentration in seven CAPL)
patients in IPD prephase and during subsequent CAPD. The linear
regression line incorporates data obtained in CAPD.
growth hormone secretion is sensitive to either serum glucose
concentration and/or intracellular glucose concentration [12].
Physiologically, the elevation of both parameters causes sup-
pression of growth hormone levels. In uremia, howevcr, growth
hormone levels are elevated under fasting conditions, and after
an oral D-glucose challenge the growth hormone is secreted
paradoxically [13, 141. This paradoxical growth hormone reac-
tion, however, is reversed in CAPD. The uremia-specific inhibi-
tion of insulin-dependent D-glucose transport into peripheral
cells [15] therefore seems to be compensated in CAPD by the
continuous peritoneal absorption D-glucose. The intracellular
glucoreceptor should now be saturated to a higher extent as it
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Fig. 4. Course of serum cholesterol concentration in seven CAPD
patients in IPD prephase and during subsequent CAPD. The linear
regression line incorporates data obtained during CAPD.
usually is in the state of uremia, which leads to the observed
suppression of growth hormone secretion after stimulation.
The response curves of blood sugar, insulin, and growth
hormone in the oral D-glucose tolerance tests indicate the
existence of a typical but mild form of maturity onset diabetes
generally known as pseudodiabetes uremica. The course of
CAPD obviously does not deteriorate this carbohydrate intoler-
ance further. One may assume that the continuous uptake of D-
glucose does not exhaust the insulin synthesis capacity. Our
findings are in accordance with similar results from Lindholm et
al 1161. It is also interesting to compare the fasting levels of
insulin and growth hormone in CAPD with hemodialysis (HD)
Carbohydrates
Body wt
Patient kg (%
no. ideal weight)
1 38.7
82%
2 42.6
108%
3 65.4
90%
4 82.4
135%
5 62.6
94%
6 55.7
96%
7 62.6
84%
58.6
(5.2)
Fat Protein
Dialysate —- Total energy uptake
(D-Olucosc) Nutrition Nutrition Nutrition —
Amount Energy Amount Energy
—
Amount Energy Amount Energy
kflkg
body wt
g/24 hr kJ/24 hr
49.9 769.9
(3.1) (47.7)
g/24 hr
137
(12.!)
k,J/24 hr
2329.2
(206)
g/24 hr
74.0
(7.3)
kJI24 hr g124 hr kJ/24 hr
39.6 673.0
(4.8) (82.0)
kg/24 hr
6588.7
24 hr
170.32816.6(277)
173.0 2660.8
(5.6) (86.2)
103.5
(8.3)
1759.2
(141)
60.2
(6.7)
2286.3
(255)
46.9 796.8
(3.7) (62.0) 7512.1 176.3
127.7 1970.9
(3,5) (54.0)
137.6
(11.3)
2339.6
(171)
73.0
(9.0)
2773.6
(308)
52.8 897.0
(5.1) (78.0)
7981.1 122.0
136.1 2100.3
(5.7) (87.9)
131.4
(6.6)
2234.!
(111)
87.0
(3.7)
3306.0
(141)
54.5 926.9
(3.0) (51.0) 8,567.3 104.0
116.9 1803.8
(6.0) (92.6)
114.8
(8.!)
1950.9
(139)
78.5
(7.2)
2983.0
(273)
50.0 850.6
(1.8) (30.0) 7588.3 121.2
89.6 1380.1
(4.3) (66.3)
143.6
(7.2)
2441.6
(122)
47.2
(3.3)
1792.5
(126)
38.7 657.2
(2.2) (38.0) 6271.4 112.6
125.8 1941.4
(5.2) (80.2)
87.8
(3.4)
1492.3
(58)
79.3
(5.0)
3014.7
(189)
59.8 1017.3
(2.4) (41.0) 465.7 119.3
7425.0 126.7
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Table 4. Fasting serum levels of D-glucose, insulin, and growth hormone in various peritoneal dialysis modalities
IPD
during
Dialysis modality
dialysis IPD interval CAPD
Normala value
MeanMean (5EM)
Serum level
D-glucose, mmoles/liter
Insulin, pU/ml
Growth hormone, nglml
4.8 (0.4)
6.6 (3.4)
5.7 (2.0)
4.3 (0.2)
5.3 (1.4)
3.8 (2.1)
4.8 (0.4)
3.8 (1.0)
4.4 (0.9)
3.1 to 6.1
7 (0 to 17)"
2.6 (0.7 to 7.3)"
a Data provided by the assay producer.
b Range.
Table 5. Insulin and growth hormone fasting levels in various dialysis regimens; comparison of data derived from the literature with the present
study
Insulin, fasting level Growth hormone, fasting level after rest
nglml
Mean (5EM) Reference
UIm1
Mean (sEM) Reference
Hemodialysis 26 (5 ,55)b
12.4 (2.7)
13 (4)
19.2 (3.6)
13 (2,0)
13.8 (1.0)"
20 (14)"
19 (6)
Glassman 1972 [23]
Marumo 1979 [24]
Samaan 1970 [14]
Richards 1977 [13]
Ganda 1976 [25]
Hampers 1966 [26]
Jontofsohn 1973 [27]
Sorge 1975 [28]
2.5 (1.9)
8.2
8.4 (1.0)
5.6 (2.0)
4.9 (0.5)
Marumo 1979 [24]
Davidson 1976 [29]
Samaan 1970 [14]
Sorge 1975 [28]
Richards 1977 [13]
17.1 x 5.9
CAPD
IPD
Controls
3.8 (1.0)
6.6 (3.4)
7 (0 to 17)a
Present study
Present study
Data sheet
(Behring Werke)
4.4 (0.9)
5.7 (2.0)
2.64 (0.7 to 73)a
Present study
Present study
Data sheet
(Behring Werke)
a Range.
SD.
data (Table 4). Table 5 depicts such a comparison with data
from recent literature. Growth hormone does riot seem to be
influenced by CAPD. Uremia-elevated levels were found in
peritoneal dialysis in each modality, as well as in HD. Fasting
insulin, however, is lower in CAPD and IPD compared to HD.
In this context one may recall that insulin has a molecular
weight of 6,000 daltons and growth hormone one of 21,500
daltons. A bidirectional transport along concentration gradients
across the peritoneum was demonstrated for "middle mole-
cules" [17]. Insulin absorption from the dialysate had gained
some practical importance through the intraperitoneal adminis-
tration of insulin in type 1 diabetes in CAPD [18].
In the investigated patients the course of serum lipids exhibit-
ed a well defined reaction to CAPD; as statistics ascertain, the
triglyceride levels are not influenced despite large scatter due to
the inclusion of hyperlipoproteinemic persons in the study.
Cholesterol increases significantly after the onset of CAPD.
The values reached indicate an enlargement of all cholesterol-
carrying lipoprotein fractions in serum. This finding agrees with
other CAPD reports regarding lipid metabolism [1, 19]. The
flooding of the acetyl CoA pool by the continuous supply of
monomeric carbohydrates (660 mmoles D-glucose and 220
mmoles lactate per day, Table 2) should increase synthetic
reactions since the energy supply is normal in these patients as
demonstrated in the dietary survey group. Because insulin
levels are reduced, due to the peritoneal insulin clearance, the
insulin-dependent synthesis of triglycerides in the liver [20—221
may not increase further. On the other hand, cholesterol
biosynthesis may be among biochemical pathways which can be
augmented further.
Whether or not the elevated cholesterol serum levels have
clinical importance with respect to the development of cardio-
vascular diseases in CAPD cannot be answered at the present
time since survival rate calculations of sufficient statistical
security are not at hand. Epidemiological investigations will
certainly clarify the situation in the future.
Summary. A total of 15 patients on maintenance CAPD were
studied to answer the question of whether or not the continuous
uptake of D-glucose via peritoneal absorption leads to long-
term alterations of metabolism. The methodology applied in-
cluded: (1) a determination of the peritoneal energy transfer
provided by D-glucose and lactate absorption and protein
excretion (15 patients); (2) a 2-week dietary survey of CAPD
conditions at home with a free choice of food (9 patients); (3)
oral D-glucose tolerance test (OGTT) with a determination of
insulin and growth hormone response; (4) follow-up of serum
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triglyceride and cholesterol levels. The results show: (1) The
net energy gain via the peritoneum amounted to 1800 kJ/24 hr if
three bags with low D-glucose (I .5%) and one bag with high D-
glucose (4.25%) were used. The energy uptake was predomi-
nantly caused by the D-glucose resorption. (2) The patients
deliberately suppressed the carbohydrate fraction in the food to
such an extent that the peritoneal D-glucose resorption was
fully compensated. (3) The carbohydrate intolerance found in
uremia in general persisted during CAPD but was not deterio-
rated further, The insulin response in the OGTT was typical for
the maturity onset type of diabetes mellitus (type 2) with
hyperinsulinism. The growth hormone, however, exhibited a
full reverse of its paradoxical reaction to an oral D-glucose
challenge found in all other maintenance dialysis conditions. (4)
Triglyceride levels were uninfluenced by the course of CAPD
remaining in the same range as in the foregoing IPD phase,
whereas cholesterol levels increased significantly after the
onset of CAPD.
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